https://orcid.org/0000-0001-5349-2203
References
- Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23(5):660–670. doi:10.1038/s41590-022-01141-1
- O’Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81. doi:10.1016/j.ctrv.2016.11.007
- Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomarker Res. 2020;8(1):1–16. doi:10.1186/s40364-020-00228-x
- Monteleone G, Maresca C, Colella M, et al. Targeting IL-34/MCSF-1R axis in colon cancer. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.917955
- DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369–382. doi:10.1038/s41577-019-0127-6
- Baghdadi M, Wada H, Nakanishi S, et al. Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells an importance of IL34 in cancer chemoresistance. Cancer Res. 2016;76(20):6030–6042. doi:10.1158/0008-5472.CAN-16-1170
- Hama N, Kobayashi T, Han N, et al. Interleukin-34 limits the therapeutic effects of immune checkpoint blockade. Iscience. 2020;23(10):101584. doi:10.1016/j.isci.2020.101584
- Fares CM, Van allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book. 2019;39:147–164. doi:10.1200/EDBK_240837